Episurf Medical EPIS B.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker EPIS B.ST. It has been listed since 5 November 2010. In the fiscal year to 31 December 2025, it reported revenue of SEK 13.5m and a net loss of SEK 58.2m. At that date it held total assets of SEK 59.8m and shareholders' equity of SEK 47.5m.

Episurf Medical AB engages in patient-specific technology for the treatment of painful joint injuries. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2010-11-05. The company is engaged in the development, manufacture and marketing of implants and surgical drilling templates used in the treatment of local cartilage damage in knee joints. The Company’s product portfolio includes the Episealer, and individually customized implant used as a cartilage replacement for early-stage patients; and Epiguide, a drill guide designed to attach to the knee’s surface, as well as related surgical tools. The personalization of implants and instruments is based on magnetic resonance imaging (MRI) and enables less invasive treatment. The process of ordering and creation of patient-specific implants and surgical instruments is covered by software suite, microiFidelity, comprising microiClinic, microiDesign and microiManufacture. The main shareholder of the Company is Serendipity Ixora Fund AB.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Ulf GrunanderIndependent Chairman of the BoardSEK 400,000
• Ms. Katarina FlodstromChief Executive Officer
• Mr. Pal RyforsInterim Chief Financial OfficerSEK 4.8m
• Mr. Patrick JamnikPresident of Episurf Medical Inc
• Mr. Fredrik ZetterbergMarketing Director
• Ms. Ylva BondeHead of QA/RA
• Prof. Dr. Leif RydDirector, since 2009SEK 800,000
• Ms. Annette Brodin RampeIndependent DirectorSEK 200,000
• Mr. Christian KruegerIndependent DirectorSEK 200,000
• Ms. Laura ShunkIndependent DirectorSEK 200,000

Overall

21

Environment

3

Social

19

Governance

42

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.